Abstract:As one of the most notorious un-druggable oncogenes, mutant KRAS impairs the transition of RAS from its active GTP-binding form to the inactive GDP-binding form, leading to sustained activation of downstream MAPK pathway and ultimately tumorigenesis. The recent approved KRASG12C inhibitors have demonstrated clinical benefits in KARSG12C mutant patients. However, the other prevalent KRAS mutations, such as KRASG12D, remain a huge unmet medical challenge. There's no approved KRASG12D specific inhibitors yet. Here we present BPI-501836, a highly potent and selective small molecular inhibitor for KRASG12D. In vitro, BPI-501836 exhibited very high potency by disrupting the KRASG12D and cRAF interaction in a cell-free assay. In cell-based assays, BPI-501836 inhibited proliferation of KRASG12D mutant cell lines with sub-nanomolar IC50 values, without affecting wide type or non-G12D KRAS mutant cell lines. Moreover, it also attenuated ERK phosphorylation in KRASG12D mutant cells. In vivo, tumor regression was observed following the administration of 6 mg/kg (iv, QW) BPI-501836 in KRASG12D human pancreatic Panc04.03 xenograft mouse models, or in the KRASG12D human pancreatic PK-59 xenograft mouse models with an intraperitoneal injection of 20 mg/kg per week. Noteworthy was the prolonged half-life of BPI-501836 observed across various species, coupled with its high distribution in tumor tissues. Moreover, sustained suppression of ERK phosphorylation in tumor tissues persisted for up to 144 hours after the last dose of BPI-501836 in both xenograft mouse models. This extended pharmacodynamic effect supports the feasibility of a once-weekly dosing schedule in clinical applications. Safety assessments conducted through a 4-week repeated infusion (intravenous, twice weekly) of BPI-501836 in beagle dog demonstrated favorable safety profiles. In conclusion, BPI-501836 emerges as a highly potent and selective KRASG12D inhibitor, exhibiting promising pharmacokinetics, pharmacodynamics, and safety profiles in pre-clinicalstudies. BPI-501836 is currently in IND-enabling stage and holds potential for further development as a therapeutic agent. Citation Format: Xiang Yang, Yuan Lu, Renqi Xu, Xiaoqiang Kong, Yongqing Sun, Xingjie Zhu, Xiaoyun Liu, Zhengyao Zou, Haibo Chen, Yanju Liu, Jialing Sun, Han Han, Cheng Yang, Jing Guo, Hong Lan, Quan Zhou, Lieming Ding, Hao Wu, Jiabing Wang. BPI-501836: A highly potent small molecule inhibitor targeting KRASG12D mutation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6512.

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3- d ]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS G12D Inhibitors

Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors

Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening

Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation

Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents

Research Progress on Small Molecule Inhibitors Targeting KRAS G12C with Acrylamide Structure and the Strategies for Solving KRAS Inhibitor Resistance

Design, Synthesis, and Evaluation of 4(1H)-Quinolinone and Urea Derivatives As KRASG12C Inhibitors with Potent Antitumor Activity Against KRAS-mutant Non-Small Cell Lung Cancer.

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Discovery, Optimization and Biological Activity Evaluation of Genipin Derivatives As Potential Kras G12d Inhibitors

Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Abstract 3325: HBW-012-D and HBW-012-E are novel, potent, selective, safe, and bioavailable KRAS G12D inhibitors with superior anti-tumor efficacy in mice

Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents

Abstract 6512: BPI-501836: A highly potent small molecule inhibitor targeting KRASG12D mutation

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity

Inhibition of GTPase KRASG12D: a review of patent literature